1,778
Participants
Start Date
October 17, 2017
Primary Completion Date
December 11, 2017
Study Completion Date
May 17, 2018
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
United Medical Associates, Binghamton
Medical Research South, Charleston
Meridan Clinical Research, LLC, Savannah
Clinical Research of South Florida, an AMR Company, Coral Gables
Coastal Clinical Research, Inc., Mobile
New Orleans Center for Clinical Research, Knoxville
Rapid Medical Research, Inc., Cleveland
Sundance Clinical Research, LLC, St Louis
Center for Pharmaceutical Research, LLC, Kansas City
Johnson County Clin-Trials, Lenexa
Heartland Research Associates, LLC - An AMR Company, Newton
Heartland Research Associates, LLC - An AMR Company, Wichita
Meridian Clinical Research, LLC, Omaha
Benchmark Research, Fort Worth
Benchmark Research, San Angelo
Martin Diagnostic Clinic, Tomball
Advanced Clinical Research, Meridian
Advanced Clinical Research, West Jordan
Anaheim Clinical Trials, Anaheim
Paradigm clinical Research Centers, Inc, Redding
Seqirus
INDUSTRY